Table 4.
Comparison of 1- and 5-Year Height in SDS from the Mean for Age (HtSDS) and Change in Height SDS (∆HtSDS) During GH Therapy, for Childhood Cancer Survivors With and Without Irradiation
| Tumor Groups: All Patients | Median Delta Height SDS (10th, 90th percentiles) | |||
|---|---|---|---|---|
| HtSDS at Start of GH |
1-Year ∆HtSDS | 5-Year ∆HtSDS | HtSDS at 5 Years of GH |
|
| Craniopharyngioma (RT + no RT) | -2.3 (-3.9, -0.4) |
0.8 (0.1, 1.5) |
1.6 (0.3, 3.0) |
-0.6 (-2.6, 1.4) |
| Leukemia (TBI) | -2.1 (-3.2, -1.0) |
0.3 (0.0, 0.7) |
0.4 (-0.6, 1.3) |
-1.8 (-3.2, -0.5) |
| Leukemia (no TBI) | -2.2 (-3.5, -0.9) |
0.5 (0.0, 0.9) |
1.0 (0.2, 1.9) |
-1.2 (-2.6, 0.3) |
| Medulloblastoma (craniospinal RT) | -2.0 (-3.6, -0.8) |
0.5 (0.1, 0.9) |
0.9 (0.0, 1.9) |
-1.0 (-3.0, 0.4) |
| Tumor Groups: Prepubertal Patients | ||||
| Craniopharyngioma (RT + no RT) |
-2.5
a
(-4.3, -0.7) |
0.8
(0.1, 1.7) |
1.6
(0.3, 3.3) |
-0.8
a
(-2.9, 1.4) |
| Leukemia (TBI) | -2.0 (-3.2, -1.2) |
0.3 (0.0, 0.9) |
0.4 (0.0, 1.7) |
-1.4 (-2.7, -0.5) |
| Leukemia (no TBI) | -2.2 (-3.2, -1.6) |
0.5 (0.1, 0.9) |
1.1 (-0.7, 1.8) |
-1.1 (-2.3, 0) |
| Medulloblastoma (craniospinal RT) | -2.4 (-4.0, -1.4) |
0.5 (-0.1, 0.8) |
0.9 (0.1, 1.7) |
-1.6 (-3.5, -0.2) |
Top panel includes all patients; bottom panel includes only patients who were prepubertal at start of GHT.
Abbreviations: RT, radiation therapy; TBI, total body irradiation; SDS, SD score.
a Data are presented as median delta height SD score (10th, 90th percentiles).